Articles
News, editorials, patient stories, and more.
This content is for informational purposes only and does not constitute medical advice. Always consult your doctor or a qualified healthcare provider before making any health decisions. Full Disclaimer
An Oral Drug Shows Long-Term Promise for a Rare Form of Autoimmune Angioedema
A December 2025 study in the Journal of Allergy and Clinical Immunology found that long-term treatment with deucrictibant, an oral bradykini...
Read More — An Oral Drug Shows Long-Term Promise for a Rare Form of Autoimmune Angioedema »Case Report: Atypical AMAN Strikes During Active Pneumonia, Prompting Urgent IVIG and Full Recovery
A case published in Cureus in November 2025 describes an unusual presentation of acute motor axonal neuropathy (AMAN) occurring simultaneous...
Read More — Case Report: Atypical AMAN Strikes During Active Pneumonia, Prompting Urgent IVIG and Full Recovery »A Rare Antibody Made This Axonal Neuropathy Nearly Untreatable — Until the Right Diagnosis Was Made
A case report from the University of Texas at San Antonio documents a highly treatment-resistant case of AMSAN in which the discovery of an...
Read More — A Rare Antibody Made This Axonal Neuropathy Nearly Untreatable — Until the Right Diagnosis Was Made »It Runs in the Family: New Data on Hashimoto's Genetic Risk
The largest familial risk study of Hashimoto's ever conducted has quantified just how much your relatives share your risk. First-degree rela...
Read More — It Runs in the Family: New Data on Hashimoto's Genetic Risk »Novartis Ianalumab First Drug to Reduce Disease Activity and Patient Burden in Sjögren's Disease Phase III Trials
Novartis announces that ianalumab, a dual-mechanism B-cell depleting antibody, achieved statistically significant reductions in Sjögren's d...
Read More — Novartis Ianalumab First Drug to Reduce Disease Activity and Patient Burden in Sjögren's Disease Phase III Trials »A Hidden Cancer Risk in APS-1: What a New Scoping Review Found About Head and Neck Malignancies
A scoping review of 19 APS-1 patients found that head and neck squamous cell carcinomas develop early, often without classic risk factors, a...
Read More — A Hidden Cancer Risk in APS-1: What a New Scoping Review Found About Head and Neck Malignancies »Antiphospholipid Syndrome Is Getting a Second Look: Emerging Therapies May Go Beyond Lifelong Blood Thinners
A new review in Arthritis & Rheumatology highlights how antiphospholipid syndrome is increasingly being understood as an antibody-mediated d...
Read More — Antiphospholipid Syndrome Is Getting a Second Look: Emerging Therapies May Go Beyond Lifelong Blood Thinners »Selective JAK1 Inhibitor Ivarmacitinib Shows Meaningful Benefit in Active Ankylosing Spondylitis Trial
A peer-reviewed study in Arthritis and Rheumatology found that ivarmacitinib, a selective JAK1 inhibitor, significantly improved symptoms in...
Read More — Selective JAK1 Inhibitor Ivarmacitinib Shows Meaningful Benefit in Active Ankylosing Spondylitis Trial »When Standard Treatments Are Not Enough: Rituximab Offers Hope for Refractory Ocular Cicatricial Pemphigoid
A case report in the journal Reports documents how rituximab, an anti-CD20 biologic, stabilized ocular cicatricial pemphigoid in a patient w...
Read More — When Standard Treatments Are Not Enough: Rituximab Offers Hope for Refractory Ocular Cicatricial Pemphigoid »Implantable Cell Therapy May Offer Path Toward Functional Cure for Addison's Disease
Research presented at ENDO 2025 describes bioprinted adrenal cortex tissue that, when implanted in animals, restored cortisol production fol...
Read More — Implantable Cell Therapy May Offer Path Toward Functional Cure for Addison's Disease »Meta-Analysis Evaluates the Efficacy and Safety of Rituximab for Primary Sjögren's Syndrome
A 2025 meta-analysis pooled data from multiple clinical trials to offer the most comprehensive picture yet of how well rituximab works for p...
Read More — Meta-Analysis Evaluates the Efficacy and Safety of Rituximab for Primary Sjögren's Syndrome »New Review Identifies Key Biomarkers for Diagnosing and Tracking ADEM and MOG Antibody Disease
A comprehensive 2025 review compiled the latest evidence on biomarkers that can improve diagnosis, predict relapses, and guide treatment for...
Read More — New Review Identifies Key Biomarkers for Diagnosing and Tracking ADEM and MOG Antibody Disease »